Alivus Life Sciences (GLS) | Stock Overview & Key Data
Alivus Life Sciences Performance Comparison
Stock Range
Today's Range
Low: ₹922.10
High: ₹943.20
on August 11, 2025
52 Week Range
Low: ₹850.00
High: ₹1,335.10
on April 7, 2025
on September 16, 2024
All-Time High: ₹1,335.10 on September 16, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR133.0B
EPS
34.48
P/E Ratio (TTM)
31.45
Forward P/E
22.31
P/B Ratio
5.23
PEG Ratio
22.31
Div. Yield
N/A
ROE
17.18%
Beta
0.160
Debt to Equity
0.63
Financial Highlights
Profitability
Gross Margin
55.55%
Operating Margin
23.53%
Profit Margin
19.21%
Returns and Earnings
Return on Assets (TTM)
11.43%
Return on Equity (TTM)
17.18%
EBITDA
INR6.5B
Net Income (TTM)
INR4.2B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR179.95
Quarterly Revenue Growth (YoY)
-14.90%
Quarterly Earnings Growth (YoY)
-19.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences GLS | 133.05B Mid-cap | -6.58% | -7.60% | -15.49% | -22.35% | -8.20% | 2.21% | 113.55% | 24.89% |
| Sun Pharmaceutical SUNPHARMA | 3.84T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.59T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Alembic APLLTD | 184.02B Mid-cap | -2.38% | -6.43% | 3.77% | 5.42% | -10.75% | -17.18% | 43.48% | -9.82% |
| Jubilant Pharmova JUBLPHARMA | 174.95B Mid-cap | -5.02% | -5.59% | 24.87% | 10.08% | 1.88% | 27.78% | 214.12% | 81.50% |
| Neuland Laboratories NEULANDLAB | 168.20B Mid-cap | 0.63% | 11.90% | 6.29% | -10.73% | -8.36% | 13.74% | 1,100.26% | 1,532.07% |
Ownership & Short Interest
Insider Ownership
76.43%
Institutional Ownership
6.57%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
63K
Average 90-Day Volume
105K
Alivus Life Sciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Alivus Life Sciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GLS's 52-week high and low?
- In the last 52 weeks, Alivus Life Sciences reached a high of ₹1,335.10 (on September 16, 2024) and a low of ₹850.00 (on April 7, 2025).
- What is the market cap and P/E ratio for GLS?
- Curious about Alivus Life Sciences's size and valuation? Its market capitalization stands at 133.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is 31.45, and the forward P/E (looking ahead) is 22.31.
- Does GLS pay dividends? If so, what's the yield?
- As for dividends, Alivus Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alivus Life Sciences's main competitors or similar companies to consider before investing?
When looking at Alivus Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.84T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.59T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Alembic
APLLTD184.02B Healthcare Drug Manufacturers - Specialty & Generic -17.18% 43.48% Jubilant Pharmova
JUBLPHARMA174.95B Healthcare Drug Manufacturers - Specialty & Generic 27.78% 214.12% Neuland Laboratories
NEULANDLAB168.20B Healthcare Drug Manufacturers - Specialty & Generic 13.74% 1,100.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alivus Life Sciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Alivus Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.18%, the Debt to Equity ratio from the most recent quarter is 0.63, and its Gross Profit Margin stands at 55.55%.
- What is the recent revenue and earnings growth for GLS?
- Looking at Alivus Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR22B. Compared to the same quarter last year (YoY), quarterly revenue grew by -14.90%, and quarterly earnings saw a YoY growth of -19.70%.
- How much of GLS stock is held by insiders and institutions?
- Wondering who owns Alivus Life Sciences stock? Company insiders (like executives and directors) hold about 76.43% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 6.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.